# Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers

> **NCT01389466** · PHASE1,PHASE2 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 346 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Step 1
- **BIOLOGICAL:** Step 2

## Key facts

- **NCT ID:** NCT01389466
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2011-11
- **Final completion:** 2011-12
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2014-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01389466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01389466, "Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01389466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*